Fisetin and Blood Pressure: Does It Raise or Lower It?

Does fisetin raise or lower blood pressure?

No human clinical trial has directly measured blood pressure changes with fisetin supplementation. The preclinical data suggest fisetin may have mild vasorelaxant effects, consistent with the broader flavonoid class it belongs to. A small human pharmacokinetic study found no significant blood pressure changes after single doses [1]. Whether fisetin meaningfully changes blood pressure in humans remains unknown; animal effects cannot be used to estimate a human effect size.

Fisetin should not be used as an antihypertensive treatment and should not replace prescribed medication. If you're on antihypertensives, discuss fisetin with your prescriber before starting. This article walks through the preclinical evidence, the human data gap, and practical guidance. For the broader safety picture, see our side effects and safety article.

Blood pressure quick answers

Reader question	What the evidence allows us to say
Does fisetin lower blood pressure?	Some animal and laboratory findings suggest vascular effects. A reproducible blood-pressure-lowering effect has not been established in human supplementation trials.
Can it raise blood pressure?	A reliable increase has not been established either; no sufficiently powered dedicated human trial answers the question.
What if I take blood-pressure medicines?	Do not replace or change prescribed treatment. Ask the prescribing clinician or pharmacist about new supplements, particularly with several medicines. See the interaction review.

For the broader tolerability picture, see side effects and measured human exposure.

The two questions readers actually ask

This article answers two questions that arrive in reader messages with roughly equal frequency.

"Can fisetin raise my blood pressure?" Usually asked by people with well-controlled hypertension who are worried a new supplement might destabilise their regimen. The short answer: no established mechanism or clinical evidence supports this concern.

"Can fisetin lower my blood pressure?" Usually asked by people who've seen marketing claims about flavonoid benefits for cardiovascular health and want to know if fisetin can substitute for or add to antihypertensive treatment. The short answer: preclinical evidence points to a possible mild vasorelaxant effect, but no controlled human trial has shown a meaningful blood pressure reduction, and fisetin shouldn't be used as antihypertensive treatment.

The honest picture is that fisetin's effect on human blood pressure hasn't been characterised in any published randomised trial. Claims in both directions rest on extrapolation from preclinical data and from related flavonoids, not on direct evidence.

What does the preclinical evidence suggest?

The preclinical cardiovascular case is stronger than it was when this article was first published, but it is still preclinical.

Direct antihypertensive evidence in rats

A 2026 peer-reviewed study tested fisetin in isolated rat aortic rings and in spontaneously hypertensive rats. Fisetin produced concentration-dependent vasorelaxation ex vivo and, after 28 days of oral dosing, lowered systolic, diastolic and mean arterial pressure in the hypertensive-rat model [7]. The investigators also reported no overt toxicity in the measured animal safety markers. This is direct blood-pressure evidence, but it does not establish an antihypertensive effect or dose in people.

Vascular senescence and endothelial function

Peer-reviewed mouse studies also connect fisetin with vascular senescence biology. Mahoney and colleagues reported improved age-related endothelial dysfunction with reduced senescence-associated signalling in old mice [2]. A 2025 diabetic-aortic-aging study likewise reported lower vascular senescence markers and improved vascular measures in mouse models, with supporting endothelial-cell experiments [8]. These studies strengthen mechanism plausibility without proving a human blood-pressure benefit.

The broader flavonoid class

Fisetin's closest chemical relatives — quercetin, kaempferol, myricetin — have been studied more extensively for blood pressure effects. A review of quercetin supplementation studies found that more recent work in hypertensive animals and people showed a blood pressure reduction after quercetin supplementation, though the effect was less consistent in people with normal blood pressure to begin with [3]. Proposed mechanisms include improved nitric oxide signalling, reduced oxidative stress, and mild ACE-inhibitory activity in vascular tissue [4]. Whether fisetin produces a similar class effect at supplement doses in humans is unstudied but plausible — and it's worth remembering that related flavonoids can differ meaningfully in potency, so this is a reasonable hypothesis, not a demonstrated effect.

What does the human evidence actually show?

Direct measurement of fisetin's blood pressure effects in a controlled human trial hasn't been published. Two data points are worth naming.

The pharmacokinetic trial

Fifteen healthy adults who received single doses of unformulated or hydrogel-formulated fisetin did not show clinically significant blood pressure changes during the 12-hour observation period [1]. Blood pressure wasn't the study's primary endpoint, and the sample size was small, but this is preliminary evidence that single-dose fisetin doesn't produce acute blood pressure effects in healthy adults.

Ongoing and registered trials

Fisetin's clinical trials, including the completed COVID-FIS trial in nursing home residents, capture routine vital sign monitoring as part of standard safety data collection [5], but a dedicated, peer-reviewed analysis of blood pressure outcomes hasn't been published. The AFFIRM trial protocol includes cardiovascular endpoints among its secondary outcomes [6]; when it publishes, it will provide the first randomised, controlled data specifically addressing how fisetin affects cardiovascular parameters in frail older women.

What should you do if you're on blood pressure medication?

If you have hypertension and are considering fisetin, the practical guidance is straightforward.

Continue your prescribed antihypertensive regimen unchanged. Fisetin is not a substitute for prescribed medication, and any potential blood pressure effect is likely too small to justify a medication change.

Discuss fisetin with your prescriber before starting. They may want to know the specific product, the dose, and why you're taking it. Some prescribers will have no concern; others may prefer you wait until your blood pressure is stable.

Monitor your blood pressure at home for the first four weeks. If it drifts meaningfully in either direction, tell your clinician. A modest reduction may be welcome; a substantial drop in someone already on antihypertensive treatment could suggest an additive effect and warrant a dose review.

Avoid starting fisetin in the same week as a new blood pressure medication. If you're starting a new antihypertensive, wait until your regimen is stable — typically two to four weeks — before adding fisetin, so any changes can be clearly attributed to one thing or the other.

Watch for lightheadedness on standing. If this happens after starting fisetin, it may reflect a mild additive drop in blood pressure. Standing up slowly, staying hydrated, and talking to your clinician are sensible responses.

Further reading: the overall fisetin evidence and safety guide. Do not change prescribed blood-pressure treatment on the basis of supplement hypotheses.

What we still don't know

Whether fisetin produces measurable blood pressure changes in humans at any dose hasn't been directly tested in a randomised trial.

Whether the vascular effects reported in recent peer-reviewed mouse studies translate to human blood pressure or vascular outcomes remains unknown [2] [8].

Whether pulsed versus continuous fisetin dosing produces different blood pressure effects is untested — different pharmacokinetic profiles could plausibly produce different vascular responses.

Whether any theoretical blood pressure effect from fisetin is additive with antihypertensive medications, or independent of them, hasn't been characterised in any interaction study.

Whether specific groups — older adults, people with existing endothelial dysfunction, people with metabolic syndrome — respond differently is unstudied. Results from ongoing trials such as AFFIRM should begin to address this.

Bottom line

Fisetin now has peer-reviewed preclinical evidence for vasorelaxation and blood-pressure lowering in hypertensive rats, plus additional mouse evidence on vascular senescence and endothelial function [7] [2]. No published human trial has established that fisetin lowers or raises blood pressure as a clinical endpoint. It should not replace prescribed antihypertensive treatment, and people taking blood-pressure medication or prone to hypotension should discuss supplemental fisetin with their prescriber.